149 related articles for article (PubMed ID: 19169272)
1. The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
Chen HB; Lu JX; Li Q; Bao YQ; Tang JL; Lu HJ; Xiang KS; Jia WP
Acta Pharmacol Sin; 2009 Feb; 30(2):242-50. PubMed ID: 19169272
[TBL] [Abstract][Full Text] [Related]
2. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
3. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
[TBL] [Abstract][Full Text] [Related]
4. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
5. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Burnier M; Zanchi A
J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
[TBL] [Abstract][Full Text] [Related]
7. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
[TBL] [Abstract][Full Text] [Related]
8. An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
García-Donaire JA; Segura J; Ruilope LM
Expert Opin Pharmacother; 2005 Aug; 6(9):1587-96. PubMed ID: 16086646
[TBL] [Abstract][Full Text] [Related]
9. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
Sasso FC; Carbonara O; Persico M; Iafusco D; Salvatore T; D'Ambrosio R; Torella R; Cozzolino D
Diabetes Care; 2002 Nov; 25(11):1909-13. PubMed ID: 12401731
[TBL] [Abstract][Full Text] [Related]
10. Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Croom KF; Plosker GL
Drugs; 2008; 68(11):1543-69. PubMed ID: 18627212
[TBL] [Abstract][Full Text] [Related]
11. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Ager EI; Wen SW; Chan J; Chong WW; Neo JH; Christophi C
BMC Cancer; 2011 Jun; 11():274. PubMed ID: 21703011
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
13. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Lehnert H; Bramlage P; Pittrow D; Kirch W
MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
[TBL] [Abstract][Full Text] [Related]
14. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Ruilope LM
Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
[TBL] [Abstract][Full Text] [Related]
15. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
16. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Hansen BV; Parving HH
Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
[TBL] [Abstract][Full Text] [Related]
19. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
20. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
